Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.USPTO grants patent to Genprex’s Reqorsa gene therapy
The protection for this patent will last until 2037. Genprex has also obtained similar patent protection for the gene therapy used with PD-L1 antibodies in Korea, and is
The protection for this patent will last until 2037. Genprex has also obtained similar patent protection for the gene therapy used with PD-L1 antibodies in Korea, and is
This is the first approved treatment for NCFB in the European Union (EU). Approval followed evaluation of data from the Phase III Aspen and Phase II Willow studies
The acquisition brings Halda’s lead candidate, HLD-0915, a clinical-stage treatment for prostate cancer, into Johnson & Johnson’s oncology portfolio. This once-daily therapy presents an opportunity to enhance patient
The fund will focus on medical technology and biopharmaceutical companies that seek to meet pressing unmet clinical needs, leveraging Sofinnova’s multi-strategy platform and investment team. It will leverage
Leqembi is a humanised anti-soluble aggregated amyloid-beta monoclonal antibody. The development follows the August 2024 approval for treating mild cognitive impairment (MCI) and mild dementia caused by Alzheimer’s
This collaboration is intended for the development of advanced biological signatures to improve targeted treatment strategies. It centres on leveraging BostonGene’s AI-powered omnimodal platform to analyse tumour molecular
The RMAT designation was based on initial data from March Bio’s ongoing multi-centre Phase II clinical trial, which indicated clinical activity and a manageable safety profile in a
The new site increases capacity and strengthens the company’s supply chain capabilities for RLTs in the US. The facility in Carlsbad, filed with the US Food and Drug
These candidates will be developed using SanegeneBio’s tissue-selective ligand and enhancer assisted delivery (LEAD) technology. The partnership focuses on advancing new therapies that can potentially be administered subcutaneously
The authorisations are granted for Gobivaz in 50 mg/0.5 mL and 100 mg/mL formulations, available in pre-filled syringes and autoinjectors. The medication is indicated for the treatment of